Trial
NCT03681951
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
Parexel
Condition
Neoplasms, Pancreatic
Intervention
GSK3145095
Why stopped
The study was terminated following an internal review of the company's current research and development portfolio.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-31